Single answer
Is Acrivon Therapeutics Inc Common (ACRV) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Acrivon Therapeutics Inc Common Stock is $21.83, which is $19.42 (805.81%) above the current price today's price.
Low target: $17.00 | High target: $30.00
Company snapshot
A quick overview of the business and its public profile.
Acrivon Therapeutics Inc a clinical stage biopharmaceutical company engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomicsbased patient responder identification platform The companys Acrivon Predictive Precision Proteomics a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates Its lead clinical candidate is ACR368 a selective small molecule inhibitor targeting CHK1 and CHK2 which is in a potentially registrational Phase 2 trial across various tumor types including platinumresistant ovarian endometrial and bladder cancer The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways such as WEE1 a protein kinase and PKMYT1 a protein serinethreonine kinase The company was incorporated in 2018 and is based in Watertown Massachusetts
Website: https://www.acrivon.com
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.14 and is down -0.0800 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.02. Cash flow to debt ratio: -22.01. Net profit margin: -9,640.45%. Inflation risk score: medium (0.70/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Acrivon Therapeutics Inc Common is $2.3M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Acrivon Therapeutics Inc Common 10 years ago, but if you had invested on 2022-11-09 when the price was $0.0000, you would have made a profit of $2.41 per share or 24,099,900.00%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.